Browsing Tag
Precision Oncology
23 posts
Verana Health and Guardant Health link genomics and real-world data to accelerate precision oncology drug
Verana Health and Guardant Health (GH) combine EHR and genomic data to accelerate oncology drug development. Read the full strategic analysis.
Abbott (ABT) closes $21bn Exact Sciences deal, making it the leader in U.S. cancer screening diagnostics
Abbott (ABT) closes its $21bn Exact Sciences acquisition, creating a $12bn+ diagnostics leader in cancer screening and precision oncology. Read the full analysis.
GlycoNex and Nippon Kayaku team up to advance next-generation ADC candidate GNX201-ADC in solid tumours
GlycoNex (4168) and Nippon Kayaku advance GNX201-ADC, a protease-activated ADC targeting solid tumours. Discover what this deal means for oncology. Read more.
FDA approval positions MyChoice CDx as key HRD test for ovarian cancer therapy selection
Myriad Genetics secures FDA approval for MyChoice CDx with Zejula. Discover how this reshapes oncology diagnostics and precision medicine markets.
Is Merck & Co., Inc. embedding artificial intelligence at the core of its oncology strategy through Tempus AI integration?
Merck expands its Tempus AI collaboration to embed artificial intelligence into oncology research. What this means for MRK, TEM, and precision medicine.
Exact Sciences stockholders approve Abbott acquisition, clearing final hurdle in $21bn cancer diagnostics deal
Exact Sciences stockholders approve Abbott’s $21 billion acquisition. Find out how the deal could reshape cancer diagnostics and investor strategy.
Exact Sciences (NASDAQ: EXAS) earnings show why Abbott moved now on a $21bn diagnostics acquisition
Exact Sciences delivered record 2025 results ahead of its Abbott acquisition. Find out why cash flow, screening scale, and timing matter now.
Acrivon Therapeutics strengthens precision oncology pipeline with ACR-368 Phase 2b success and new AP3-enabled candidates
Find out how Acrivon Therapeutics is advancing precision oncology with positive ACR-368 Phase 2b data, EU trial expansion, and new AP3-enabled pipeline candidates.
Natera boosts ctDNA and lymphoma detection capabilities through Foresight Diagnostics acquisition
Find out how Natera’s acquisition of Foresight Diagnostics could redefine ultra-sensitive cancer detection and reshape the future of MRD testing.
Black Diamond Therapeutics reports strong early Phase 2 response for silevertinib in first-line NSCLC patients
Discover how Black Diamond Therapeutics’ silevertinib achieved a 60% response in first-line lung cancer and why its upcoming glioblastoma trial could reshape targeted oncology.